J. W. Coons Advisors LLC Sells 100 Shares of Zoetis Inc. (NYSE:ZTS)

J. W. Coons Advisors LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 6.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,453 shares of the company’s stock after selling 100 shares during the quarter. J. W. Coons Advisors LLC’s holdings in Zoetis were worth $237,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Hancock Whitney Corp raised its holdings in Zoetis by 0.3% during the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares during the period. Strategy Asset Managers LLC raised its stake in shares of Zoetis by 3.5% during the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the period. VeraBank N.A. raised its stake in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after purchasing an additional 62 shares during the period. Procyon Advisors LLC lifted its holdings in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its stake in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after purchasing an additional 65 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 3.1 %

Shares of NYSE:ZTS opened at $165.51 on Tuesday. The firm has a market capitalization of $74.12 billion, a PE ratio of 30.26, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The firm has a fifty day moving average of $166.30 and a 200 day moving average of $177.78.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZTS. UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Piper Sandler decreased their target price on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.